Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis

[Display omitted] Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a new class of oral medicines being developed for the treatment of anemia in chronic kidney disease (CKD) patients. This study aimed to compare the efficacy and safety of HIF-PHI vs epoetin and darbepoetin in CKD...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Pharmacological research 2020-09, Vol.159, p.105020-105020, Article 105020
Hauptverfasser:	Zheng, Qiyan, Yang, Huisheng, Sun, Luying, Wei, Ruojun, Fu, Xinwen, Wang, Yahui, Huang, Yishan, Liu, Yu Ning, Liu, Wei Jing
Format:	Artikel
Sprache:	eng
Schlagworte:	Anemia Chronic kidney disease Darbepoetin Epoetin HIF prolyl-hydroxylase inhibitors Life Sciences & Biomedicine Non-dialysis Pharmacology & Pharmacy Science & Technology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!